Endobronchial Ultrasound Guided Transbronchial Needle Aspiration and PD-L1 Yields

医学 肺癌 腺癌 支气管内超声 活检 PD-L1 癌症 放射科 细胞学 免疫疗法 肿瘤科 病理 内科学
作者
Lara M. Khoury,Kristin N. Sheehan,William I. Mariencheck,Katherine Gershner,Matthew Maslonka,Angela G. Niehaus,Scott Isom,Christina Bellinger
出处
期刊:Lung [Springer Science+Business Media]
标识
DOI:10.1007/s00408-024-00692-4
摘要

Abstract Purpose Immunotherapy is a leading approach for treating advanced non-small cell lung cancer (NSCLC) by targeting the PD-1/PD-L1 checkpoint signaling pathway, particularly in tumors expressing high levels of PD-L1 (Jug et al. in J Am Soc Cytopathol 9:485–493, 2020; Perrotta et al. in Chest 158: 1230–1239, 2020). Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive method to obtain tissue for molecular studies, including PD-L1 analysis, in unresectable tumors (Genova et al. in Front Immunol 12: 799455, 2021; Wang et al. in Ann Oncol 29: 1417–1422, 2018). This study aimed to assess the adequacy of PD-L1 assessment in EBUS-TBNA cytology specimens. Methods Data was collected retrospectively from patients who underwent EBUS-TBNA between 2017 and 2021 for suspected lung cancer biopsy. Samples positive for NSCLC were examined for PD-L1 expression. EBUS was performed by experienced practitioners, following institutional guidelines of a minimum of five aspirations from positively identified lesions. Sample adequacy for molecular testing was determined by the pathology department. Results The analysis involved 387 NSCLC cases (149 squamous cell, 191 adenocarcinoma, 47 unspecified). Of the 263 EBUS-TBNA specimens tested for PD-L1, 237 (90.1%) were deemed adequate. While 84% adhered to the protocol, adherence did not yield better results. Significantly higher PD-L1 adequacy was observed in squamous cell carcinomas (93.2%) compared to adenocarcinoma (87.6%). The number of aspirations and sedation type did not correlate with PD-L1 adequacy in either cancer type, but lesion size and location had a significant impact in adenocarcinomas. Adenocarcinoma exhibited higher PD-L1 expression (68%) compared to squamous cell carcinoma (48%). Conclusion EBUS-TBNA offers high yields for assessing immunotherapy markers like PD-L1, with satisfactory adequacy regardless of NSCLC subtype, lesion size, or location.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
白川完成签到 ,获得积分10
5秒前
5秒前
vampire完成签到,获得积分10
5秒前
南音发布了新的文献求助10
7秒前
8秒前
8秒前
斯文未来完成签到,获得积分10
9秒前
9秒前
认真的蜜粉完成签到,获得积分10
10秒前
10秒前
雷EX1完成签到,获得积分10
11秒前
无花果应助洛希极限采纳,获得10
11秒前
yolo发布了新的文献求助10
15秒前
上官若男应助科研通管家采纳,获得10
17秒前
顾矜应助高高采纳,获得20
17秒前
充电宝应助科研通管家采纳,获得10
17秒前
17秒前
赘婿应助科研通管家采纳,获得10
17秒前
17秒前
17秒前
17秒前
loii应助科研通管家采纳,获得10
17秒前
17秒前
17秒前
小二郎应助科研通管家采纳,获得10
17秒前
汉堡包应助科研通管家采纳,获得10
18秒前
ding应助科研通管家采纳,获得10
18秒前
Owen应助科研通管家采纳,获得10
18秒前
Emily发布了新的文献求助100
18秒前
18秒前
今后应助科研通管家采纳,获得10
18秒前
华仔应助科研通管家采纳,获得10
18秒前
18秒前
21秒前
娇娇尚发布了新的文献求助30
23秒前
RennyZ发布了新的文献求助10
23秒前
yeah发布了新的文献求助10
24秒前
Hello应助大大方方的采纳,获得10
24秒前
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Chemistry and Physics of Carbon Volume 18 800
The Organometallic Chemistry of the Transition Metals 800
Leading Academic-Practice Partnerships in Nursing and Healthcare: A Paradigm for Change 800
The formation of Australian attitudes towards China, 1918-1941 640
Signals, Systems, and Signal Processing 610
Research Methods for Business: A Skill Building Approach, 9th Edition 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6425127
求助须知:如何正确求助?哪些是违规求助? 8242850
关于积分的说明 17524883
捐赠科研通 5479593
什么是DOI,文献DOI怎么找? 2893969
邀请新用户注册赠送积分活动 1870186
关于科研通互助平台的介绍 1708179